Fosun International Ltd - Company Profile
Powered by 
All the sales intelligence you need on Fosun International Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Fosun International Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Fosun International Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Fosun International Ltd (Fosun) is a global innovation-driven consumer group. The company engages in various sectors, including health, happiness, wealth, and intelligent manufacturing. Its major products and services encompass pharmaceuticals, health management, tourism, leisure, fashion, insurance, asset management, and intelligent manufacturing. The company's products and services cater to families worldwide, serving industries such as healthcare, lifestyle, and financial services. Fosun operates through a network of subsidiaries and investments across different sectors. It has a presence in the Chinese mainland, Portugal, and other countries and regions. Fosun is headquartered in Hong Kong.
Headquarters
Hong Kong
Address
Room 808, ICBC Tower, 3 Garden Road, Hong Kong City, 999077
Website
www.fosun.com
Telephone
852 2846 9888
No of Employees
103,900
Industry
Financial Services
Ticker Symbol & Exchange
656 (HKG)
Revenue (2024)
$24.1B
-9.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-438%
(2024 vs 2023)
Market Cap*
$5.3B
Net Profit Margin (2024)
XYZ
-496.9%
(2024 vs 2023)
* As of and is in US$
Fosun International Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Non-life Insurance | Healthcare Services | s |
| Life and Non-life Reinsurance | Secondary Market Investments | Fosun |
| Medical and Pharmaceutical Products | Venture Capital and Private Equity Investments | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In June, Henlius announced regulatory approval in China for a perioperative gastric cancer indication for serplulimab, enabling chemotherapy-sparing adjuvant treatment. |
| 2026 | Regulatory Approval | In May, Henlius noted a China regulatory approval for a pertuzumab biosimilar, strengthening its globally approved HER2 breast cancer portfolio. |
| 2026 | Contracts/Agreements | In May, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. secured an exclusive global option agreement with AriBio to develop and commercialize AR1001 for Alzheimer’s disease. |
Competitor Comparison
| Key Parameters | Fosun International Ltd | Ping An Insurance (Group) Company of China Ltd | China Pacific Insurance (Group) Co Ltd | Huatai Insurance Group Co Ltd | China National Pharmaceutical Group Corp |
|---|---|---|---|---|---|
| Headquarters | Hong Kong | China | China | China | China |
| City | Hong Kong City | Shenzhen | Shanghai | Beijing | Beijing |
| State/Province | - | Guangdong | Shanghai | Beijing | Beijing |
| No. of Employees | 103,900 | 258,806 | 91,639 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Guo Guangchang | Chairman | Executive Board | - | 58 |
| Gong Ping | Chief Financial Officer; Director; President | Executive Board | 2021 | 50 |
| Pan Donghui | Director; Chief Human Resource Officer; President | Executive Board | 2023 | 56 |
| Xu Xiaoliang | Co-Chief Executive Officer; Director | Executive Board | - | 52 |
| Chen Qiyu | Director; Co- Chief Executive Officer | Executive Board | - | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer